Negative Results: Relaxin ® Clinical Trials for Scleroderma

Phase III Relaxin Trial Did Not Reach Primary Endpoint.
Relaxin is of no value for the treatment of scleroderma.

Author: Shelley Ensz. Scleroderma is highly variable. See Types of Scleroderma. Read Disclaimer

"Scleroderma has again proven to be an extremely difficult disease for which to develop a therapeutic treatment." Connetics 10-8-00.

Related Links

Scleroderma Research Registries. ISN.

Scleroderma Treatments & Clinical Trials. ISN.

Ineffective or Unproven Treatments for Scleroderma. ISN.

Go to Scleroderma Clinical Trials: Positive Results
Recent Donors
See ISN News for recent donors, including memorials for
Christine Kane, Joleen M. Cascaden.

SCLERO.ORG is the world leader for trustworthy research, support, education and awareness for scleroderma and related illnesses, such as pulmonary hypertension. We are a service of the nonprofit International Scleroderma Network (ISN), which is a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team, or Volunteer. Donations may also be mailed to:

International Scleroderma Network (ISN)
7455 France Ave So #266
Edina, MN 55435-4702 USA

Email [email protected] to request our Welcome email, or to report bad links or to update this page content.

TOLL FREE HOTLINE 1-800-564-7099
Free to U.S. and Canadian Callers. Ask for our Free Info Packet by mail or email!
Scleroderma, Pulmonary Arterial Hypertension, and related illnesses.
Privacy Policy.

The most important thing in the world to know about scleroderma is!
Donate Now
Copyright 1998-2017, International Scleroderma Network. AKA Scleroderma from A to Z and SCLERO.ORG. All Rights Reserved.